EUVIMEDDescubrir EUVIMED
Open access · CC BY-NC-ND 4.0

Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein

Frances Rocamora, Chen-Lin Hsieh, Sanne Schoffelen, Johnny Arnsdorf, Eric A Toth, Abdul S Yunus, Thomas E Cleveland iD, Sara Petersen Bjørn, Mina Ying Min Wu, Noel G McElvaney, Bjørn Gunnar Rude Voldborg, Thomas R Fuerst and 1 more

Biotechnology and Bioengineering · 2026

DOI: 10.1002/bit.70285 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2026. Written by Frances Rocamora and 12 co-authors. Institution: Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California, USA. Major MEDLINE topics: alpha 1-Antitrypsin, Recombinant Proteins, Protein Engineering. 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NHLBI NIH HHS, Novo Nordisk Foundation, Novo Nordisk Fonden.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Alpha‐1‐antitrypsin (A1AT) is a multifunctional, clinically important, high‐value therapeutic glycoprotein that can be used for the treatment of many diseases, such as A1AT deficiency, diabetes, graft‐versus‐host disease, cystic fibrosis, and various viral infections. Currently, the only U.S. food and drug administration‐approved treatment for A1AT disorders is intravenous augmentation therapy with human plasma‐derived A1AT (pdA1AT). In addition to its limited supply, this approach poses a risk of infection transmission, since it uses therapeutic A1AT harvested from donors. To address these issues, we sought to generate recombinant human A1AT (rhA1AT) that is comparable to its plasma‐derived counterpart using glycoengineered Chinese Hamster Ovary (geCHO‐L) cells. By perturbing nine key genes that are part of the CHO glycosylation machinery and expressing the human ST6GAL1 and A1AT genes, we obtained stable, high producing geCHO‐L lines that produced rhA1AT having a highly similar glycoprofile to pdA1AT. Additionally, the rhA1AT demonstrated in vitro activity and in vivo half‐life comparable to commercial pdA1AT. Thus, we anticipate that this platform will help produce human‐like recombinant plasma proteins, thereby providing a more sustainable and reliable source of therapeutics that are cost‐effective and better‐controlled regarding purity, clinical safety, and quality.

Subjects

MeSH terms (MEDLINE)

alpha 1-AntitrypsinRecombinant ProteinsProtein EngineeringHumansAnimalsCricetulusCHO CellsCricetinaeGlycosylationMice

Author keywords

alpha‐1‐antitrypsinbiologicglycoengineeringglycosylationtherapeutic protein

Substances

alpha 1-AntitrypsinRecombinant ProteinsSERPINA1 protein, human

Authors and institutions

  • Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California, USA.
  • Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA.
  • Center for Molecular Medicine, University of Georgia, Athens, Georgia, USA.
  • Department of Biotechnology and Biomedicine, National Biologics Facility, Technical University of Denmark, Lyngby, Denmark.
  • Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, USA.
  • NeuImmune, Inc., Sykesville, Maryland, USA.

ORCID profiles: Thomas E Cleveland, Nathan E Lewis

Funding

  • NHLBI NIH HHS
  • Novo Nordisk Foundation
  • Novo Nordisk Fonden
  • National Heart, Lung, and Blood Institute

Cite

APA

Rocamora, F., Hsieh, C. L., Schoffelen, S., Arnsdorf, J., Toth, E. A., Yunus, A. S., Cleveland, T. E., Bjørn, S. P., Wu, M. Y. M., McElvaney, N. G., Voldborg, B. G. R., Fuerst, T. R., & Lewis, N. E. (2026). Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70285

Vancouver

Rocamora F, Hsieh CL, Schoffelen S, Arnsdorf J, Toth EA, Yunus AS, et al. Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70285

BibTeX
@article{Rocamora2026,
  author = {Rocamora, Frances and Hsieh, Chen-Lin and Schoffelen, Sanne and Arnsdorf, Johnny and Toth, Eric A and Yunus, Abdul S and Cleveland, Thomas E and Bjørn, Sara Petersen and Wu, Mina Ying Min and McElvaney, Noel G and Voldborg, Bjørn Gunnar Rude and Fuerst, Thomas R and Lewis, Nathan E},
  title = {Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein},
  journal = {Biotechnology and Bioengineering},
  year = {2026},
  doi = {10.1002/bit.70285}
}
Start for free →